Benzinga | Mar 24, 2021 08:03AM EDT

Clover Biopharmaceuticals And Dynavax Announce First Participants Dosed In SPECTRA Global Phase 2/3 Clinical Trial For Adjuvanted S-Trimer COVID-19 Vaccine Candidate

Clover Biopharmaceuticals (Clover), a global clinical-stage biotechnology company developing transformative biologics such as vaccines and therapeutics for the world's most debilitating diseases, and Dynavax Technologies Corporation ((Dynavax, NASDAQ:DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced the first participants have been dosed in Clover's SPECTRA trial (Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine), a global Phase 2/3 clinical trial evaluating the efficacy, safety and immunogenicity of Clover's protein-based S-Trimer COVID-19 vaccine candidate adjuvanted with Dynavax's CpG 1018 plus alum.